Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors.

ABSTRACT: Activation of immune checkpoint pathways and limited T- cell infiltration result in immunological escape of tumors. Although immune checkpoint inhibitors are currently approved for several types of cancers, the response rate is often limited by the lack of tumor specific T-cells within the malignant tissue. Therefore, new combinatorial strategies are needed to enhance the clinical benefit of immune checkpoint inhibitors. We have previously developed PeptiCRAd, an oncolytic vaccine platform capable of directing the immune response toward tumor epitopes. In this study, we evaluated whether the platform could be used to increase the response rate to checkpoint inhibitors in both highly immunogenic and poorly immunogenic tumors, such as melanoma and triple negative breast cancer (TNBC). We rep

SUBMITTER: Feola S 

PROVIDER: S-EPMC6136871 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature